文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

嵌合抗原受体 T 细胞（CAR T 细胞）。

CD19 CAR T Cells.

机构信息

Center for Cell Engineering, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.

出版信息

Cell. 2017 Dec 14;171(7):1471. doi: 10.1016/j.cell.2017.12.002.

DOI:10.1016/j.cell.2017.12.002
PMID:29245005
Abstract

CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor. To view this Bench to Bedside, open or download the PDF.

摘要

嵌合抗原受体（CARs）是一种用于治疗目的的免疫细胞重编程的人工受体。它由三个用于抗原识别、T 细胞激活和共刺激的典型结构域组成。CAR cDNA 被遗传整合到 T 细胞基因组中。自体 CAR T 细胞是从患者外周血 T 细胞中产生的，并在受体中扩增以消除靶向肿瘤。要查看此从实验室到临床的转化，请打开或下载 PDF。

相似文献

[1]
CD19 CAR T Cells.

Cell. 2017-12-14

[2]
CAR therapy: the CD19 paradigm.

J Clin Invest. 2015-9

[3]
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Nature. 2017-3-2

[4]
CAR T-cell therapy effective in B acute lymphoblastic leukaemia.

Lancet Oncol. 2017-6

[5]
[Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014-12

[6]
Chimeric antigen receptor T-cell therapy for ALL.

Hematology Am Soc Hematol Educ Program. 2014-12-5

[7]
Marshaling the immune system to eliminate minimal residual disease in B-ALL.

J Natl Cancer Inst. 2014-9-10

[8]
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.

J Hematol Oncol. 2016-11-25

[9]
CAR T-cells merge into the fast lane of cancer care.

Am J Hematol. 2016-1

[10]
CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.

Leuk Lymphoma. 2019-5

引用本文的文献

[1]
SARDH in the 1-C metabolism sculpts the T-cell fate and serves as a potential cancer therapeutic target.

Cell Mol Immunol. 2025-8-20

[2]
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells.

Front Immunol. 2025-1-17

[3]
YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies.

Cell. 2025-1-23

[4]
Piloting a scale-up platform for high-quality human T-cells production.

Front Cell Dev Biol. 2024-7-12

[5]
Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies.

Mol Ther Nucleic Acids. 2024-5-20

[6]
Cathepsin B causes trogocytosis-mediated CAR T cell dysfunction.

bioRxiv. 2024-8-22

[7]
Magnetite nanoparticles: an emerging adjunctive tool for the improvement of cancer immunotherapy.

Explor Target Antitumor Ther. 2024

[8]
Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.

Clin Transl Med. 2024-5

[9]
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.

Haematologica. 2024-12-1

[10]
A comprehensive study for selecting optimal treatment modalities for blood cancer in a Fermatean fuzzy dynamic environment.

Sci Rep. 2024-1-22

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索